IgA nephropathy (IgAN) and HenochSchonlein purpura (HSP)
IgAN is a common form of glomerulonephritis which is defined by the deposition of IgA in the glomerular mesangium [ 1,2]. Haematuria is t h e initial clinical hallmark of t h e disease. Early in the course of the disease episodes of visible haematuria are common and often coincide with mucosal infection (typically of the respiratory tract, and less commonly of t h e gastrointestinal tract). T h e IgA deposits may provoke little glomerular injury, but more often the consequences of IgA deposition are glomerular inflammation Abbreviations used: /l1,3GT, fl1-3-galactosyltransferase; HSP, Henoch-Scholein purpura; IgAN, IgA nephropathy; pIgA, polymeric IgA. *To whom correspondence should be addressed.
followed by sclerosis and progressive loss of function. T h i s is commonly a chronic process leading inexorably to renal failure [ 11.
HSP, despite its name which is perpetuated for historical reasons, is a multisystem disease with a characteristic vasculitic rash. Renal involvement is common and the findings in the kidney are virtually identical with those in IgAN The studies described in this report were developed to investigate two questions which need to be addressed if there is to be progress in our understanding of glomerular IgAl deposition in IgAN and HSP: what is the site of origin in the IgA immune system of the deposited pIgAl?
What is the mechanism of mesangial pIgAl deposition?
Site of plgA production in lgAN
T o investigate the site of origin of the increased circulating pIgAl in IgAN we studied J-chain synthesis which appears to be a rate-limiting step in the assembly of pIgA [ 131.
We developed in situ hybridization for J-chain mRNA to study pIgA synthesis in mucosal and non-mucosal immune systems in IgAN. Duodenal lamina propria obtained by endoscopic biopsies, bone marrow trephine biopsies and tonsils were all available from patients with IgAN and matched controls. pIgA production was identified by defining J-chain mRNA expression in IgA-producing plasma cells using non-isotopic double-labelling techniques [ 141 (Figure 1 ). Unexpectedly, pIgA synthesis defined in this way was consistently down-regulated in mucosal lamina propria [ 151 and up-regulated in bone marrow [16] . It was also up-regulated in tonsillar tissue [ 171. The tonsil has previously been thought to play a key role in IgAN; there is some evidence that tonsillectomy may reduce the incidence of frank haematuria. However, tonsillar IgA production is modest compared with that of marrow or mucosal lamina propria; if tonsillar overproduction were primary, it might be expected that marrow pIgA production would be unchanged or suppressed. Furthermore IgAN does occur after tonsillectomy. These points argue against a primary role for the tonsil in IgAN. 
It
is not yet clear whether suppressed mucosal pIgAl production is the primary abnormality in IgAN, perhaps allowing increased antigen penetration to stimulate an exaggerated marrow response, or is a secondary down-regulation in response to primary marrow hyperresponsiveness.
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Mechanism of mesangial IgA deposition
The
This has led to the concept that pIgAl may be deposited by a mechanism other than classical antigen-antibody interactions. Altered glycosylation of IgAl has been proposed as a candidate defect [18, 19] .
IgA I glycosylation
IgAl like all immunoglobulins is a glycoprotein. It is heavily glycosylated, containing complex N-glycans, but is unique among major serum immunoglobulins for its 0-linked glycans, which are restricted to the hinge region and therefore not present in IgAZ [ZO] . The hinge contains 10 0-glycosylation sites linked to serine residues; the 0-glycans contain GalNAc with or without terminal galactose Gal in the b1-3 position: serine-GalNAc(/jl-3) Gal [21] . Each 0-glycan may have variable sialylation [22] .
Altered 0-glycosylation could have significant structural and functional influences because of the pivotal position of the hinge region; changes in three-dimensional structure could alter interactions with the antigen-binding site as well as interactions with Fc receptors, complement and matrix proteins.
IgAI glycosylation in lgAN
We have developed lectin-binding assays based on lectins specific for 0-glycans GalNAc [24] . Our initial studies relied on isolation of IgAl by jacalin binding. Since jacalin is itself a lectin which recognizes hinge-region glycans on IgA1, there was concern that jacalin was isolating unrepresentative IgAl . However, the lectin-binding assays applied to total IgA provide the same findings (A. C. Allen, unpublished work). Preliminary studies with fluorophoreassisted carbohydrate electrophoresis, which maps 0-glycans after their release from IgAl by hydrazinolysis at 60"C, confirm a characteristic 0-glycan pattern in serum IgAl in these patients which requires further definition (A. C. Allen, unpublished work). Others have recently reported reduced sialylation of released Galfll3GalNAc (using HPLC after hydrazinolysis), with in vitro evidence that the altered sialylation influenced IgAl aggregability [25] . This work provides support for the notion that altered IgAl hinge 0-glycans do indeed have functional influence. Definitive structural confirmation of the Galbl-3GalNAc abnormality indicated by the lectin-binding studies is now required.
lgAl glycosylation in HSP
Lectin-binding studies of serum IgAl from patients with HSP show the same pattern as in IgAN (Figure 2 ), but only in those subjects with HSP who have renal involvement [26] . T h e lectin binding in HSP without nephritis is no different from matched controls. Patients with glomerulonephritis that is not associated with IgA deposition also do not show differences from controls in lectin binding of serum IgA1.
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Limitations of serum IgA I -glycosylation studies
Studies of serum IgAl are inevitably indirect; the pathogenic IgAl molecules are by definition in the kidney and it cannot be guaranteed that circulating IgAl molecules are representative. However, the very small amount of IgAl that can be eluted from human renal biopsy material are not sufficient for the necessary analysis, and opportunities for study of larger samples of IgAN kidney must be awaited.
I -3-galactosyltransferase (I ,3GT)
T h e glycosyltransferases are a family of highly specific enzymes "271. Addition of Gal in the pl-3 configuration to GalNAc is catalysed by pl,3GT. If the defect implied by lectin-binding studies is indeed reduced terminal galactosylation of GalNAc, reduced /31,3GT activity would be predicted in IgA plasma cells. (An alternative could be subsequent removal of Gal, but there is no evidence for any excess glycosidase activity in these patients.) We developed a functional assay for b1,3GT in which the substrate was isolated IgAl hinge region stripped of Gal by b-galactosidase, and the capacity of cell lysates to regalactosylate the substrate was measured by reduction in binding of a lectin (Vicza villosa) specific for GalNAc [28] . In peripheral blood B-cells from patients with IgAN there was reduced 11,3GT activity compared with matched controls ( Figure  3A) . Furthermore B-cell b1,3GT activity correlated significantly with the lectin-binding abnormality in serum IgAl from the same patients ( Figure 3B) . B-cells isolated from peripheral blood will only contain a minority of IgA-producing cells, and more specific studies, particularly of marrow IgA-producing cells, are required to confirm this finding. Nevertheless these studies suggest that a post-translational enzyme defect may be a key abnormality in IgAN.
Implications of altered 0-glycosylation of lgAl
There are a number of putative mechanisms by which an altered hinge region could change IgAl behaviour and promote glomerular IgAl deposition and subsequent injury. These include: (i) reduced clearance of circulating IgAl ; the hepatic asialoglycoprotein receptor, the main clearance mechanism for ciculating IgAl recognizes IgAl through hinge-region galactose [29, 30] ; (ii) altered aggregability or polymerization of IgAl Vicia villosa lectin binding of serum lgAl (AU) [25] ; (iii) modified interactions with complement (complement deposition in association with IgA is common in IgAN, yet IgA is a rather poor activator of complement [31, 32] ); (iv) modified interactions with glomerular matrix proteins (the IgA deposits are characteristically extracellular);
(v) altered engagement of Fca receptors, both on circulating myeloid inflammatory cells and also on mesangial cells, where an Fca receptor has recently been described but not yet fully characterized [33, 34] . However, it should be emphasized that as yet there is little or no evidence to support these most interesting speculations. Functional data are required before the structural abnormality of the IgAl hinge can be confirmed as an important pathogenic element in IgAN. 
